Considering GR antagonists, relacorilant has shown interesting results in improving hypertension and impairment of glucose metabolism, with a safety profile apparently better than mifepristone, the only actually available GR antagonist, although further evidences from wider phase III studies are required. Here, NR3C1 is linked to hypertensive disorder.